NEW YORK (AP) ¿ Shares of Vanda Pharmaceuticals Inc. skyrocketed in premarket trading Thursday after the company said regulators approved its schizophrenia drug Fanapt. Rockville, Md.-based Vanda plans to begin shipping the drug to pharmacies later this year. The news sent Vanda shares surging nearly tenfold to $11.25 from $1.08. The stock last traded above $11 in November 2007, and has not been above $6.59 in the last year. Fanapt, or iloperidone, was more effective than a sugar pill in controlling symptoms of schizophrenia in clinical testing. The drug is an atypical antipsychotic, a group of relatively new drugs. Other drugs in the group include risperidone, which Johnson & Johnson markets as Risperdal, and Eli Lilly & Co.'s Zyprexa. Approval for the drug was delayed in July because the Food and Drug Administration concluded Fanapt was too similar to drugs already on the market. The agency also required more testing at the time. The most common side effects for Fanapt in clinical testing were dizziness, dry mouth, fatigue, nasal congestion, sleepiness, low blood pressure, rapid heartbeat, and mild weight gain.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Food & Drink
Starbucks Price Target Raised at Cowen Ahead of Earnings
An accounting change expands gross margins, which Cowen says investors aren't appreciating.
Shake Shack Tumbles on Downgrade to Neutral From Buy at Longbow
Shake Shack is downgraded to neutral from buy at Longbow Research on valuation concerns.